🚨 As most of you know, I hate Moderna and loathe their CEO, Stephane Bancel. Responsible for my Mom's death and getting ZERO attention. All eyes on Pfizer and Albert Bourla - I want all the monsters rounded up but COME ON! Of course I know, through the work of Ms Destiny @dezzie_rezzie, Moderna is a US Military Operation funded by Flagship Pioneering venture capital followed none other than DARPA. I have attached one of her slides. Anyway, that's NO DAMN EXCUSE. Monsters throughout their organization. I asked Grok what vaccines were in their pipeline - and the list is HORRIFYING. Go ahead @SecKennedy and @calleymeans - stay focused on food. MODERNA PIPELINE: Moderna’s vaccine development pipeline (as of October 2026) focuses primarily on respiratory, latent, enteric, bacterial, and public-health targets using its mRNA platform. The company has several commercial products and multiple candidates in clinical stages.⁠ Commercial / Approved Vaccines: SPIKEVAX® — COVID-19 vaccine mNEXSPIKE® — next-generation COVID-19 vaccine mRESVIA® — RSV vaccine mFLUSIVA® (mRNA-1010) — seasonal influenza vaccine (FDA-approved for adults 50+; available for the 2026–2027 season) mCOMBRIAX® — flu + COVID combination vaccine (approved in some markets such as the EU) Active Vaccine Development Pipeline: Respiratory Vaccines mRNA-1018 — pandemic flu vaccine (Phase 3; in collaboration with CEPI) mRNA-1365 — RSV + hMPV vaccine (Phase 1) mRNA-1345 — RSV vaccine for pediatrics (Phase 2) Enteric Viruses mRNA-1403 — norovirus vaccine (Phase 3; the NOVA 301 trial did not meet the statistical bar for early success at an interim analysis in July 2026 and is continuing with an additional cohort; final readout delayed) mRNA-1405 — norovirus vaccine (Phase 2) Latent Viruses mRNA-1647 — CMV vaccine for transplant recipients (Phase 2) mRNA-1189 — EBV vaccine to prevent infectious mononucleosis (Phase 2) mRNA-1195 — EBV vaccine targeting long-term sequelae (Phase 2) mRNA-1645 — HIV vaccine (Phase 1; in collaboration with IAVI) Bacterial mRNA-1975 and mRNA-1982 — Lyme disease vaccines (both Phase 2) Public Health / Emerging Pathogens mRNA-1469 — Bundibugyo ebolavirus vaccine (Phase 1) mRNA-1215 — Nipah vaccine (Phase 1; with NIH) mRNA-1769 — Mpox vaccine (Phase 2) Notes: Moderna’s broader pipeline also includes oncology programs (e.g., the personalized neoantigen therapy intismeran autogene / mRNA-4157 in partnership with Merck, which has multiple Phase 2/3 studies in melanoma, NSCLC, and other cancers) and rare-disease therapeutics. These are typically categorized separately from prophylactic vaccines. Pipeline status can change with trial readouts and regulatory decisions; the most current details are on Moderna’s site